This technology is a non-invasive method for quantifying nuclear imaging and tomographic brain images acquired with the use of injected contrast agents without the need for blood sampling.
Current methods for nuclear imaging, including positron emission tomography (PET) and computed tomography (CT), require invasive real-time blood sampling for quantifying time-series brain images. Typically, sampling is done via an arterial catheter, which is costly, risky to patients, time consuming, and requires a specialist. While some techniques exist that reduce number of required blood samples from 20 down to 1-3 for some tracers, the overall requirement of blood sampling limits clinical utility of many research tracers. Currently, there are no available methods that are totally non-invasive that do not rely on blood sampling.
This technology is a non-invasive method for estimating tracer blood concentration for nuclear imaging. This model eliminates the need for blood sampling by utilizing data obtained directly from the imaging signal combined with physiological parameters specified in the patients’ electronic health record (EHR). For this, the imaging data and electronic health records can be used to predict one or more anchors to generate an arterial input function (AIF) for the radioligand. An optimized framework is then able to quantify the various images. As a result, this technology provides an effective, non-invasive method for quantifying image data.
This technology has been validated retrospectively using EHR and positron emission tomography (PET) imaging from 95 patients who underwent neuroreceptor mapping.
Patent Pending (US 20170039706)
IR CU14274
Licensing Contact: Jerry Kokoshka